Watch CABA. Know when insiders buy.
One email the day a filing lands. Free.
CABA
Cabaletta Bio, Inc.
2.91
−0.36 −11.01%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · shorts 38
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $493.4MP/E —DIV YIELD —FCF YIELD -31.26%REV TTM —NET INCOME −$181.3MNET CASH —52W 1.74 – 4.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$52M | −$51M | — | -0.34 | −$41.5M | $0 | −$41.5M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$44.3M | −$43.5M | — | -0.39 | −$42.6M | $0 | −$42.6M | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$42.6M | −$41.9M | — | -0.35 | −$35.3M | $205K | −$35.5M | Mar 23 |
| Q3 2025 · Sep 30 | — | — | — | −$46.6M | −$44.9M | — | -0.44 | −$34.5M | $78K | −$34.6M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$45.9M | −$45.1M | — | -0.73 | −$30.4M | $161K | −$30.6M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$37.1M | −$35.9M | — | -0.71 | −$30.8M | $785K | −$31.6M | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$33.8M | −$32.6M | — | -0.65 | −$23.1M | $376K | −$23.5M | Mar 23 |
| Q3 2024 · Sep 30 | — | — | — | −$33M | −$30.6M | — | -0.62 | −$20.3M | $253K | −$20.6M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$30.3M | −$27.6M | — | -0.56 | −$20.8M | $770K | −$21.6M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$28M | −$25M | — | -0.51 | −$24M | $812K | −$24.8M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$23.1M | −$20.9M | — | -0.47 | −$16.4M | $185K | −$16.6M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$18.7M | −$16.4M | — | -0.37 | −$12.6M | $65K | −$12.7M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$172.2M | −$167.9M | — | -2.10 | −$131.1M | $1.2M | −$132.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$125.1M | −$115.9M | — | -2.34 | −$88.2M | $2.2M | −$90.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$74.7M | −$67.7M | — | -1.65 | −$53.5M | $687K | −$54.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$54.1M | −$53M | — | -1.81 | −$46.4M | $2.5M | −$48.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$46.3M | −$46.3M | — | -1.80 | −$34.1M | $1.2M | −$35.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$33.8M | −$33.3M | — | -1.44 | −$26.8M | $635K | −$27.4M | — | — |
Every number comes from Cabaletta Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.